

CLAIMS

1. A gene expression-inducing fusion protein, characterized in that it comprises, firstly, a
5 ribonucleic acid-binding peptide domain and a domain for activating the post-transcriptional expression of the gene and, secondly, a domain enabling delocalization to the cytoplasmic membrane.

10 2. The fusion protein as claimed in claim 1, characterized in that the expression-activating domain is a translation-activating domain.

15 3. The fusion protein as claimed in either of claims 1 and 2, characterized in that the domain enabling delocalization to the cytoplasmic membrane is a farnesylation domain.

20 4. A nucleic acid comprising a sequence encoding a protein as claimed in any one of claims 1 to 3.

25 5. An expression vector comprising a nucleic acid as claimed in claim 4.

6. A recombined cell comprising a nucleic acid as claimed in claim 4 or an expression vector as claimed in claim 5.

30 7. A cell line of recombined cells comprising a nucleic acid as claimed in claim 4 or an expression vector as claimed in claim 5, in particular SKHep and HeLa cell lines.

35 8. A cell expressing a reporter gene and an effector gene, the reporter gene comprising a binding site for a polypeptide and at least one gene of interest, and the effector gene encoding an inducer fusion protein as claimed in any one of claims 1 to 3

comprising at least said polypeptide recognized by the binding site.

9. The cell as claimed in claim 8, in which the
5 cell is eukaryotic and the polypeptide is noneukaryotic.

10. The cell as claimed in either of claims 8 and 9, in which the reporter gene is expressed from a
10 bicistronic RNA comprising a first cistron and a second cistron.

11. A nonhuman transgenic organism comprising a nucleic acid as claimed in claim 4 or a plasmid as
15 claimed in claim 5.

12. A modulatable permanent external in vitro method for controlling post-transcriptional gene expression induction in a recombined cell or in a
20 nonhuman transgenic tissue comprising a nucleic acid comprising a sequence encoding a fusion protein as claimed in any one of claims 1 to 3, or comprising an expression vector comprising said nucleic acid, by modulating the state of post-translational modification
25 of the fusion protein using an appropriate inhibitor of said post-translational modification.

13. A kit for screening agents, comprising at least one cell as claimed in any one of claims 6 to 10.
30